NCT04834375.

Study name	Randomised open investigation determining steroid dose (ROIDS‐Dose)
Methods	Trial design: randomised, open‐label trial Sample size: 142 Setting: probably inpatient Language: English Number of centres: single‐centre Type of intervention (treatment/prevention): treatment
Participants	Inclusion criteria Adults ≥ 18 years old COVID‐19 infection confirmed by positive PCR test Hypoxaemia defined by an oxygen saturation < 94% or the need for supplemental oxygen Exclusion criteria Corticosteroid use for > 48 h within the past 15 days prior to enrolment Use of steroids with doses > the equivalent to dexamethasone 6 mg Use of immunosuppressive drugs Pregnant women Chronic oxygen use Known history of dexamethasone allergy Do‐not‐resuscitate/do‐not‐intubate orders Patient or proxy cannot consent
Interventions	Details of intervention Dose: dexamethasone 6 mg daily for 10 days Route of administration: IV Treatment details of control group (e.g. dose, route of administration): dexamethasone 0.2 mg/kg/d IV (maximum 20 mg daily) for 10 days Concomitant therapy: no information
Outcomes	Primary outcome: all‐cause mortality at 28 days
Starting date	19 March 2021
Contact information	Carlos X Rabascall, MD: 5164655400 Email: crabascallay@northwell.edu
Notes	Recruitment status: recruiting Prospective completion date: 19 April 2022 Date last update was posted: 8 April 2021 Sponsor/funding: Northwell Health